Hims and hers He faces the scrutiny of legislators for an ad for their weight loss offers that is scheduled to operate during the Super Bowl on Sunday.
Sens. Dick Durbin, d -ill., And Roger Marshall, Republican of Kan., Wrong a letter to the Food and Medicines Administration of the United States. UU. On Friday they express their concern about an “next announcement” that “runs the risk to deceive patients by omitting any safety or side.
The announcement of Hims & Hers, which the company launched online at the end of January, is called “System sick” and abruptly criticize the weight loss industry of $ 160 billion. Shows images of existing weight loss medicines known as LPG-1, including injection pens that are seen as Novo Nordisk's Blockbuster Drug Ozempic Diabetes.
The announcement affirms that these medications have “priced for profits, not patients” and points to medications for the weight loss of hyms & hers as “affordable” and “controlled by the doctor.”
“We are complying with the existing law and we are happy to continue working with the Congress and the new administration to fix the broken health system and ensure that patients have quality, safe and affordable health options,” said a spokesman for HEMS & Hers to CNBC in a statement.
The senators do not mention HIMS & that of their name in their letter, but they refer to some of the images in the ad, including “images of an injection pen with distinctive features that reflect an existing brand medication.”
“Nowhere in this promotion there is some dissemination of secondary effect, risk or security information as typically required in a pharmaceutical announcement,” the senators wrote. “In addition, for only three seconds during the commercial one, the flash screen in a small and barely readable source, that these products are not approved by the FDA.”
Scott Brunner, CEO of the Alliance for Pharmacy Compilation, said Friday that the announcement of Hims & Hers is consistent with the pharmaceutical advertising of “help to search.”
“The announcement of the Hims Super Bowl does not promote a specific medication or medication and, therefore, is not obliged to provide information on side effects or risks,” Brunner said in a statement. “Instead, he encouraged viewers to consult with a medical care provider, which aligns with the FTC guidelines for non -specific ads 'search for help'.”
HIMS & Hers began offering compound semaglutid sure.
HIMS & HERS shares jumped more than 170% last year, thanks to the demand for LPG-1. They closed 5% on Friday, lifting the company's market capitalization to around $ 9.5 billion.
GLP-1 compounds are usually much cheaper and can serve as an alternative for patients who are sailing for complex supply obstacles and irregular insurance coverage. HIMS & HERS sells semaglutida composed of less than $ 200 a month.
The FDA does not review the safety and effectiveness of compound products, which are personalized alternatives to brand medications designed to meet the specific needs of a patient. Composite products can also occur when brand treatments are scarcity.
The semaglutida is currently in shortage, according to the FDA.
Durbin and Marshall said the ads for the brand's GLP-1 medications include “significant dissemination of risks for patients on side effects and contraindications, including warnings about the possible gallbladder, pancreas, vomiting, diarrhea and other implications.”
A statement on the Durbin website says that the announcement in question seems to exploit an escape “with respect to drug promotions composed by Telesalud companies.”
Senators said that the FDA can have the authority to take compliance measures against marketing that could deceive patients, and plan to introduce a new legislation to address regulatory lagoons.
LOOK: A new study reveals why patients stop taking GLP-1 obesity medications
